Patents - Akebia Therapeutics Inc v Fibrogen, Inc,
Vadadustat t Structure Wikimedia Commons Source Wikipedia Licensed by Meodipt Jane Lambert Patents Court (Lord Justice Arnold) Akebia Therapeutics Inc v Fibrogen, Inc [2020] EWHC 866 (Pat) (20 April 2020) This was a claim by Akebia Therapeutics Inc.(“Akebia”) and Otsuka Pharmaceutical Co. Ltd. (“Otsuka”) to revoke 6 patents held by FibroGen Inc. ("FibroGen"). The reason why they sought the revocation of those patents is that they wished to market their own product vadadustat . FibroGen's exclusive licensee, Astellas Pharma Inc (“Astellas”) brought quia timet infringement proceedings against Akebia, Otsuka and FibroGen. The proceedings came on before Lord Justice Arnold between 2 and 19 March 2020. His lordship delivered judgment on 20 April 2020. The Patents The patents in suit were as follows: Family A Family B WO 03/053997 (“WO 997”) WO 2004/108121 (“WO 121” ) EP (UK) No 1,463,823 (“EP 823”) EP (U...